McKesson Corporation stock (US58155Q1031): Apollo investment reshapes medical-surgical unit as shares hover above USD 730

McKesson Corporation shares on the NYSE traded above USD 730 on Wednesday after the United States-based group closed a USD 1.25 billion minority investment from Apollo funds in its Medical-Surgical Solutions business, setting a reference valuation for a potential spin-off and refocusing its core distribution franchise.

McKesson Corporation shares traded around the mid-USD 730 range on the New York Stock Exchange on Wednesday, with MarketBeat citing an opening price of USD 735.76 for MCK as of 06/03/2026, keeping the United States healthcare distributor in focus following the closing of a significant transaction in its medical-surgical arm. According to MarketBeat, McKesson remains covered by a broad group of Wall Street analysts, with the stock still viewed as part of the large-cap US healthcare universe that is closely watched by domestic institutional investors.

The latest corporate milestone for the Irving, Texas-based group is the completion of a strategic deal with Apollo funds in its Medical-Surgical Solutions (MMS) unit, which management highlighted in a press release from 06/02/2026. In that statement, McKesson announced that it had closed a USD 1.25 billion preferred equity investment from Apollo-managed funds in MMS, giving the investor a minority interest and crystallizing a roughly USD 13 billion enterprise valuation for the business according to subsequent coverage.

The transaction is structured via preferred equity and gives Apollo funds a stake of approximately 13 percent in MMS, according to analysis that extrapolates the USD 1.25 billion investment against the implied USD 13 billion valuation of the medical-surgical operation. While McKesson will retain control of the unit, the company presented the move as a way to highlight the value of MMS independently from its core US pharmaceutical distribution activities and to prepare the business for greater strategic flexibility over time.

In its 06/02/2026 release from Irving, McKesson framed the Apollo deal as a strategic investment designed to support future growth initiatives for Medical-Surgical Solutions and to sharpen the group’s overall portfolio focus. Commentary from external analysis platforms has underscored that this step could act as a precursor to a spin-off of MMS into a separate public company, with the new valuation framework providing a reference point if the unit is ultimately listed on a US exchange.

For US investors, the home-country anchor remains the NYSE listing under the ticker MCK, where the shares trade in US dollars and are also tracked by major indices and sector benchmarks. McKesson is headquartered in Irving, Texas, and positions itself as one of the key healthcare distribution and services players in the United States, with its primary listing falling under US securities regulation and disclosures filed with the Securities and Exchange Commission.

According to MarketBeat data as referenced on 06/03/2026, the stock’s analyst coverage features a group of 17 research houses, with fourteen carrying Buy-equivalent recommendations and three rating the shares at Hold, alongside an average price target of USD 968.87. While those figures are consensus-based rather than issued by a single firm, they underline the extent to which the US investment community continues to analyze McKesson following the MMS transaction, as the group refines its portfolio between pharmaceuticals distribution and adjacent healthcare solutions.

On the shareholder side, there has also been activity in institutional positions and insider holdings around the time of the Apollo deal. MarketBeat notes that Anchor Capital Advisors LLC cut its MCK stake by 3.8 percent in the fourth quarter, as disclosed in a recent SEC filing, a move that illustrates how some US asset managers are rebalancing healthcare exposure after a strong run in several large-cap names. In parallel, Marketscreener, citing a Form 4 filing, reported that McKesson executive vice president and chief strategy and business development officer Thomas L. Rodgers sold 822 shares in the company on 06/01/2026 for total proceeds of USD 604,420, an individual transaction that nonetheless remains small relative to McKesson’s overall market capitalization.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: McKesson
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Irving, United States
• Core markets: United States pharmaceutical distribution and medical-surgical supply
• Key revenue drivers: US pharmaceutical distribution, specialty pharmacy solutions, and medical-surgical products
• Home exchange/listing venue: New York Stock Exchange (MCK)
• Trading currency: USD

McKesson Corporation: core business model

McKesson Corporation operates as a large-scale healthcare distributor and services provider, generating most of its revenue from supplying pharmaceuticals, specialty therapies, and medical-surgical products to US pharmacies, hospitals, and healthcare providers.

Recent corporate actions

The closing of the Apollo funds investment in the Medical-Surgical Solutions business is the most notable recent corporate action, announced and completed on 06/02/2026 and positioned as a way to support MMS growth while refining McKesson’s overall portfolio mix. The deal follows several years of broader portfolio reshaping, in which McKesson has gradually concentrated its activities in North American distribution and related services, while exploring structural options for non-core operations; the MMS step fits into that trajectory by partially separating a business that could ultimately stand on its own as a public company if the market environment is supportive.

McKesson Corporation in peer comparison

Within the US healthcare distribution space, McKesson competes primarily with AmerisourceBergen, now operating under the Cencora name, and Cardinal Health, both of which share a focus on large-scale pharmaceutical supply and related services for providers. While detailed valuation metrics for each peer vary by date and source, sector commentary from Barchart on 05/30/2026 noted that McKesson had underperformed the Dow Jones Industrial Average over the prior 12 months, even as analysts remained largely constructive on the stock’s medium-term prospects. The implied MMS valuation of around USD 13 billion highlighted by the Apollo transaction provides an additional point of comparison by illustrating how the market might isolate one of McKesson’s segments relative to peers that still report more integrated business structures.

Conclusion

The closing of the USD 1.25 billion preferred equity investment from Apollo funds into McKesson’s Medical-Surgical Solutions business provides fresh visibility on the value of one of the company’s key segments and underscores the United States group’s willingness to reshape its portfolio. In parallel, share-price levels above USD 730 on the NYSE and continued consensus coverage with an average target closer to USD 970 highlight how the market is weighing this transaction alongside broader sector dynamics and recent insider and institutional activity. For investors following US healthcare distributors and their peers, McKesson’s MMS deal and any subsequent structural steps will likely remain a central reference point when comparing business models and valuation frameworks across the group’s competitive set.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.